Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SW 1115C3

Next Previous
Drug Profile

SW 1115C3

Alternative Names: mRNA-based personalised cancer vaccines; Neoantigen antigen mRNA tumour vaccine; Personalised mRNA tumour vaccine; SW-1115C3

Latest Information Update: 08 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Stemirna Therapeutics
  • Class Cancer vaccines; RNA vaccines
  • Mechanism of Action Gene transference; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Non-small cell lung cancer; Oesophageal cancer

Most Recent Events

  • 08 Nov 2023 SW 1115C3 is still in clinical phase for Non-small-cell-lung-cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in China (SC, Injection) (NCT03908671)
  • 08 Nov 2023 SW 1115C3 is still in clinical phase for Oesophageal-cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease) in China (SC, Injection) (NCT03908671)
  • 20 Sep 2023 Pharmacodynamics data from a phase I trial in Oesophageal cancer and Non-small cell lung cancer presented at the 7th Annual International Cancer, Immunotherapy Conference (CRI-ENCI-AACR-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top